Document is current
Any future updates will be listed below
-
Authors
Artetxe-Zurutuza, Aizpea
Iturrioz-Rodriguez, Nerea https://orcid.org/0000-0003-3698-9570
Elizazu, Joseba https://orcid.org/0000-0002-6859-0970
Toledano-Pinedo, Mireia
Porro-Pérez, Alicia
De Goñi, Irati
Elua-Pinin, Alejandro
Schäker-Hübner, Linda
Azkargorta, Mikel
Elortza, Felix
Iriepa, Isabel
Lòpez-Muñoz, Francisco
Moncho-Amor, Veronica
Hansen, Finn K.
Sampron, Nicolás
Marco-Contelles, Jose Luis
Matheu, Ander
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI22/01905, DTS24/00153)
Deutsche Forschungsgemeinschaft (GRK2873)
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2019-105813RB-C21)
- License Information
-
More Information
Article History
Received: 25 November 2024
Revised: 28 February 2025
Accepted: 18 March 2025
First Online: 4 April 2025
Competing interests
: Some of the authors are part of the patent Histone deacetylase derivatives for the treatment of cancer Submission number: 300480865; Application number: EP23382368.1. Authors - Marco Contelles, José Luis; Toledano Pinedo, Mireia; Porro Pérez, Alicia; Amendros Requena, Pedro; Iriepa Canalda, Isabel; Diez Iriepa, Daniel; López Muñoz, Francisco; Iturrioz Rodríguez, Nerea; Moncho Amor, Verónica; Samprón Lebed, Nicolás; Carrasco García, Estefania; Artetxe Zurutuza, Aizpea; Matheu Fernández, Ander.
: This study was approved by the Clinical Research Ethics Committee of the Basque Country (CEIm-E, protocol PI2023104) and adhered to the tenets of the Declaration of Helsinki. All processes involving animals were subjected to approval by the Research Animal Care of Biogipuzkoa Institute.
